Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.

Hu X, Li S, Yang G, Liu H, Boden G, Li L.

PLoS One. 2014 Feb 12;9(2):e87096. doi: 10.1371/journal.pone.0087096. eCollection 2014. Review.

2.

Clinical potential of aldose reductase inhibitors in diabetic neuropathy.

Hamada Y, Nakamura J.

Treat Endocrinol. 2004;3(4):245-55. Review.

PMID:
16026107
3.

A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.

Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D, Mari E, Benedetti MM, Tognoni G, Liberati A.

Diabet Med. 1996 Dec;13(12):1017-26.

PMID:
8973882
4.

Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.

Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS.

Mini Rev Med Chem. 2016;16(2):120-62. Review.

PMID:
26349493
5.
6.

Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.

Chalk C, Benstead TJ, Moore F.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004572. Review.

PMID:
17943821
7.

Aldose reductase inhibitors: the end of an era or the need for different trial designs?

Pfeifer MA, Schumer MP, Gelber DA.

Diabetes. 1997 Sep;46 Suppl 2:S82-9. Review.

PMID:
9285505
8.

Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.

Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R.

Ann Intern Med. 1993 Jan 1;118(1):7-11.

PMID:
8416161
9.

Aldose reductase, still a compelling target for diabetic neuropathy.

Oates PJ.

Curr Drug Targets. 2008 Jan;9(1):14-36. Review.

PMID:
18220710
10.

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.

Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.

Diabetes Care. 2006 Jul;29(7):1538-44.

PMID:
16801576
12.

Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.

Jaspan JB, Towle VL, Maselli R, Herold K.

Metabolism. 1986 Apr;35(4 Suppl 1):83-92.

PMID:
3083212
13.

WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.

Airey M, Bennett C, Nicolucci A, Williams R.

Cochrane Database Syst Rev. 1996 Apr 22;(1):CD002182. Review.

PMID:
17636697
14.

Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years.

Didangelos TP, Karamitsos DT, Athyros VG, Kourtoglou GI.

J Diabetes Complications. 1998 Jul-Aug;12(4):201-7.

PMID:
9647338
15.

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.

Hotta N, Kawamori R, Fukuda M, Shigeta Y; Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group.

Diabet Med. 2012 Dec;29(12):1529-33. doi: 10.1111/j.1464-5491.2012.03684.x.

16.

Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.

Airey M, Bennett C, Nicolucci A, Williams R.

Cochrane Database Syst Rev. 2000;(2):CD002182. Review. Update in: Cochrane Database Syst Rev. 1996;(1):CD002182.

PMID:
10796870
17.
18.

Potential use of aldose reductase inhibitors to prevent diabetic complications.

Zenon GJ 3rd, Abobo CV, Carter BL, Ball DW.

Clin Pharm. 1990 Jun;9(6):446-57. Review.

PMID:
2114249
19.

Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.

Faes TJ, Yff GA, DeWeerdt O, Lanting P, Heimans JJ, Bertelsmann FW.

J Neurol. 1993;240(3):156-60.

PMID:
8482988
20.

Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.

Gupta P, Verma N, Bhattacharya S, Mahdi AA, Usman K, Tiwari S, Bhardwaj K.

Can J Diabetes. 2014 Feb;38(1):22-5. doi: 10.1016/j.jcjd.2013.07.021.

PMID:
24485209

Supplemental Content

Support Center